(Q33513713)

27 July 2017

1 reference

title

Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics (English)

1 reference

27 July 2017

0 references

Roberto dell'Omo

2

0 references

Ciro Costagliola

object named as

Ciro Costagliola

1

0 references

author name string

Mario R Romano

3

1 reference

27 July 2017

Michele Rinaldi

4

1 reference

27 July 2017

Lucia Zeppa

5

1 reference

27 July 2017

Francesco Parmeggiani

6

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Pharmacotherapy

27 July 2017

published in

1 reference

27 July 2017

volume

10

1 reference

27 July 2017

issue

16

1 reference

27 July 2017

page(s)

2663-2677

1 reference

Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Role of the non-neuronal cholinergic system in the eye: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effects of multiple dosing of epinephrine on aqueous humor dynamics in human eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

A single-blind randomised trial comparing adrenaline 1.0% with dipivalyl epinephrine (propine) 0.1% in the treatment of open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Changes in retinal blood flow by topical administration of 0.1% dipivefrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effects of apraclonidine on aqueous humor dynamics in human eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Desipramine Lowers Tritiated Para-Aminoclonidine Binding in Platelets of Depressed Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

The effect of topical glaucoma medications evaluated by perimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effects of intraocular dapiprazole in the rabbit eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Primary drug treatment for glaucoma: beta-blockers versus other medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Atenolol 4% eye drops and glaucoma. A double-blind short-term clinical trial of a new beta1-adrenergic blocking agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Timolol hemihydrate: a new formulation of timolol for the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Acute Pulmonary Edema Associated with Ocular Metipranolol Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Metipranolol-associated granulomatous anterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Topical timolol decreases plasma high-density lipoprotein cholesterol level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Ocular hypotensive efficacy and safety of once daily carteolol alginate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Risk factors and open-angle glaucoma: classification and application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Risk factors for glaucoma onset and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

The number of people with glaucoma worldwide in 2010 and 2020

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Comparison of the ocular beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

Improved systemic safety and risk–benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903300103

10.1517/14656560903300103

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference